Gene therapy experiments put on “clinical hold”BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7231.336 (Published 05 February 2000) Cite this as: BMJ 2000;320:336
- James Ciment
- New York
The Food and Drug Administration (FDA) temporarily shut down a series of human gene therapy experiments at the University of Pennsylvania last month following the death of Jesse Gelsinger, an 18 year old man from Arizona who was being treated for a liver disorder.
The order to place the university's entire gene therapy programme on indefinite “clinical hold” came two days after inspectors issued a report noting 18 specific violations of government protocols.
The administration said …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial